Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Food on Erdafitinib PK in Healthy Subjects
NCT03066687Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2017
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of erdafitinib in urothelial carcinoma (UC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration at 366 hours, Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time at 366 hours and 1 more. Started Mar 2017; status: completed.
02
Drugs
erdafitinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03066687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03066687.